0
0
WASHINGTON — In a major development for the regulatory oversight of rare-disease treatments, The New England Journal of Medicine (NEJM) on Monday retracted a landmark 2021 study on the vasculitis drug Tavneos (avacopan). The retraction follows a sweeping U.S. Food and Drug Administration (FDA) investigation which revealed that primary endpoint clinical data for multiple patients were altered after the study database was finalized, and that key research personnel had been inappropriately unblinded.
The medical journal confirmed that two academic authors requested the retraction after the FDA’s Center for Drug Evaluation and Research (CDER) uncovered evidence that the published paper no longer accurately reflected the true underlying trial data. The decision significantly escalates pressure on pharmaceutical giant Amgen, which acquired the drug’s original developer, ChemoCentryx, in 2022. It follows an aggressive regulatory push by the FDA, which has already proposed completely withdrawing Tavneos from the U.S. market due to mounting concerns regarding its safety and actual effectiveness.
Unblinded Personnel and Altered Data: The FDA Findings
The retraction centers on the Phase 3 ADVOCATE trial, the sole pivotal study used to secure the FDA’s October 2021 approval of Tavneos. The oral medication was approved as an add-on therapy alongside standard treatments like glucocorticoids (steroids) to treat adults suffering from severe, active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis—a rare, life-threatening autoimmune disease that causes severe inflammation and destruction of small blood vessels.
According to regulatory documents published by the FDA, agency investigators discovered that unblinded study personnel manipulated the final results for nine specific patients. This data re-adjudication took place after the trial database had been locked, a practice that fundamentally violates standard clinical trial integrity.
In its formal Notice of Opportunity for a Hearing sent to Amgen, the FDA alleged that the original, unmanipulated data analysis failed to show statistical significance for the drug’s efficacy. The agency asserted that the post-lock alterations were specifically designed to make the product appear effective when the true data did not support that conclusion. Furthermore, the FDA stated that ChemoCentryx withheld the original, unaltered analysis when submitting its New Drug Application (NDA), which constitutes an introduction of untrue statements of material fact.
“CDER can no longer conclude that there is, or has ever been, a valid demonstration that Tavneos is effective for its approved use,” the agency noted in its public docket.
Evolving Safety Signals: Liver Damage and Fatalities
Beyond the critical data integrity failures, federal regulators are responding to an alarming postmarketing safety profile. On March 31, 2026, the FDA issued an urgent drug safety communication identifying 76 confirmed cases of serious drug-induced liver injury (DILI) possessing a reasonable causal link to Tavneos use.
The real-world outcomes of these cases include:
-
74 serious clinical outcomes
-
54 patient hospitalizations
-
8 confirmed patient deaths
Additionally, the FDA highlighted seven biopsy-confirmed cases of vanishing bile duct syndrome (VBDS)—three of which were fatal. VBDS is a rare, devastating condition characterized by the progressive, irreversible destruction of the internal bile ducts within the liver, leading to severe bile stasis and liver failure. Notably, neither fatal liver injury nor VBDS was listed as a potential outcome in the drug’s original prescribing information, framing this as an entirely new and severe safety signal.
Independent Experts React: “A Most Unusual Signal”
For healthcare professionals, the compounding issues of a high-profile journal retraction and severe post-approval organ toxicity strike at the core of clinical trust.
“In this instance, the FDA has determined that the rate of adverse events seen post-marketing, and an unusual adverse event like vanishing bile duct syndrome, have made the safety-efficacy ratio unacceptable,” said Dr. Allan Gibofsky, MD, JD, a former chair of the FDA’s Arthritis Advisory Committee and co-director of the Clinic for Inflammatory Arthritis and Biologic Therapy at the Hospital for Special Surgery, who was not involved in the original trial.
In an independent interview discussing the regulatory climate surrounding the drug, Dr. Gibofsky emphasized how rare it is for approval to be challenged in this manner. “Further, the FDA has taken the position that upon re-analysis of the original data, the efficacy originally shown in the pivotal clinical trial was, in fact, not demonstrated. This assertion is most unusual.”
In rare diseases like ANCA-associated vasculitis, clinical decisions are inherently fragile because they depend on a very small baseline of published evidence. When the primary pillar of that evidence is retracted, physicians are forced to re-evaluate whether the drug’s true clinical benefits outweigh its severe hepatic risks.
Public Health Implications and Patient Advice
The public health impact of this development is substantial, illustrating that drug safety and evaluation do not terminate at the moment of market approval. Ongoing postmarketing surveillance is designed precisely to catch rare, severe side effects that may not surface in limited clinical trial cohorts.
Crucially, health authorities emphasize that patients currently prescribed Tavneos should not abruptly discontinue their medication without first consulting their specialist. Halting vasculitis treatment suddenly can trigger severe, life-threatening flare-ups of blood vessel inflammation, potentially damaging vital organs like the kidneys and lungs.
Instead, the FDA advises healthcare professionals to actively discuss the evolving safety and efficacy data with their patients, reviewing alternative treatment regimens while the formal regulatory review proceeds.
Critical Symptoms to Monitor
Patients taking Tavneos should contact their prescribing physician immediately if they develop any signs of underlying liver dysfunction, including:
-
Yellowing of the eyes or skin (jaundice)
-
Unusually dark or tea-colored urine
-
Severe skin itching (pruritus)
-
Right-sided abdominal pain or tenderness
-
Persistent nausea, vomiting, or unexplained fatigue
Limitations and Amgen’s Counter-Response
While the journal retraction and the FDA’s proposed market withdrawal represent an unprecedented challenge for Tavneos, the regulatory process is complex and takes time. The drug remains legally available on the U.S. market for now, and the current findings do not automatically mean the drug provides zero therapeutic value to every individual patient currently taking it.
Amgen has strongly defended the therapeutic profile of the drug. The biotech giant has commissioned an independent, third-party research firm to perform a comprehensive reassessment and re-adjudication of the ADVOCATE trial data. Amgen plans to formally submit these independent findings to the FDA as part of its legal response.
Under federal administrative procedures, Amgen maintains the right to request a formal evidentiary hearing before the FDA Commissioner to contest CDER’s withdrawal proposal. The drug will remain commercially accessible until Amgen either chooses a voluntary market withdrawal or the FDA Commissioner issues a final, mandatory order of removal following the conclusion of the legal proceedings.
References
- https://www.reuters.com/legal/litigation/medical-journal-retracts-paper-amgens-tavneos-drug-trial-after-fda-findings-2026-06-29/
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
